期刊文献+

抗HIV药物的筛选评价方法 被引量:6

Screening and evaluating system of anti-HIV drugs
暂未订购
导出
摘要 随着对艾滋病致病机制的深入研究,越来越多新的抗艾滋病病毒(HIV)药物进入临床试验,但大量抗HIV药物的应用也导致了耐药性问题的出现。因此,建立高通量快速的抗HIV药物筛选平台对研究新的抗HIV药物非常重要。本文综述了目前抗HIV药物研究中常用的体外和体内筛选模型,重点阐述了体外以病毒复制特异性功能活动或特定结构作为靶点的筛选系统及其评价方法。 With understanding of mechanism of HIV infection, more and more new anti-HIV agents are developed and used in clinical experiments. However, the abuse of anti-HIV drugs was causing serious drug-resistance problem, so it is very important to develop new high-throughput screening system for drug discovery. In this review the commonly used in vitro and in vivo anti-HIV agents screening models are outlined, particularly the in vitro screening system targeting the specific activity or protein structure in viral production.
出处 《国外医学(药学分册)》 2007年第3期170-173,共4页 Foreign Medical Sciences(Section of Pharmarcy)
关键词 抗HIV药物 筛选评价方法 动物模型 anti-HIV agents screening and evaluating system animal model
  • 相关文献

参考文献21

  • 1刘海霞,李在村,吴昊.抗HIV药物的新发展[J].国外医学(病毒学分册),2005,12(4):117-120. 被引量:4
  • 2Hayami M,Igarashi T,Kuwnta T,et al.Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use[J].Leukemia,1999,13(Suppl 1):S42-S47.
  • 3Taggart BR,Harrington P,Hollingshesd M.HIV hollow fiber SCID model for antiviral therapy comparison with SCID/hu model[J].AntiviralRes,2004,63(1):1-6.
  • 4Kageyama S,Kurokawa M,Shiraki K,et al.Extract of Prunella vulgaris spikes inhibits HIV replication at reverse transcription in vitro and can be absorbed from intestine in vivo[J].Antivir Chem Chemother,2000,11(2):157-164.
  • 5Kempf MG,Jones J,Heil ML,et al.A high-throughput drug screening system for HIV-1 transcription inhibitors[J].J Biomol Screen,2006,11(7):807-815.
  • 6Kutsch O,Levy DN,Bates PJ,et al.Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription[J].Antimicrob Agents Chemother,2004,48(5):1652-1663.
  • 7Oehsenbauer-Jambor C,Jones J,Heil M,et al.T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication[J].Biotechniques,2006,40(1):91-100.
  • 8Au TK,Collins RA,Lam TL,et al.The plant ribosome inactivating proteins lnffin and saporin are potent inhibitors of HIV-1 integrase[J].FEBS Lett,2000,471(2/3):169-172.
  • 9Nielsen H,Pedemen S,Kjems J.Molecular strategies to inhibit HIV-1 replication[J].Retrovirology,2005,2(1):10.
  • 10Piana S,Carloni P.Conformational flexibility of the catalytic Asp dyad in HIV-1 protease:an abinitio study on the free enzyme[J].Proteins,2000,39(1):26-36.

二级参考文献26

  • 1郑永唐,贲昆龙.抗人类免疫缺陷病毒药物的研究进展[J].大自然探索,1998(4):80-86. 被引量:5
  • 2Wensing AMJ, van de Vijver DAMC, Asjo B, et al, for the SPREAD Programme. Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug resistance: the CATCHStudy. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris,France. Abstract LB01.
  • 3Collins P, Shiveley L, Anderson C, Bethell R. Analysis of the genotypes of viruses isolated from patients after 10 days monotherapy with SPD754. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004;San Francisco, Calif. Abstract 526.
  • 4Bethell R, Adams J, De Muys J, et al. Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754.In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco,Calif. Abstract 138.
  • 5Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. July 10, 2002;288(2): 181-188.
  • 6Gruzdev B, Rakhmanova A, de Dier K, Comhaire S, Baede-Van Dijk P, van T Klooster G. TMC125 is a highly potent non-nucleoside reverse transcriptase inhibitor (NNRTI) in antiretroviral therapy (ART)-naive, HIV-1 infected subjects. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Ill. Abstract I-668.
  • 7Gathe J, Kohlbrenner VM, Pierone G, et al. Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Mass. Abstract 179.
  • 8Wohl DA. CROI 2003: emerging HIV therapies. The Body Pro'scoverage of the 10th Conference on Retroviruses and Opportunistic Infections; February 14, 2003.
  • 9Arasteh K, Clumeck N, Pozniak A, et al. Antiretroviral activity,safety and pharmacokinetics of TMC114, a next-generation HIV-1protease inhibitor (PI), in multiple PI-experienced patients. In:Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract LB16.
  • 10Peeters M, Van Baelen B, De Meyer S, et al. TMC114/RTV activity in multiple PI-experienced patients: correlation of baseline genotype, phenotype, pharmacokinetics, and IQ with antiviral activity at day 14. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004;San Francisco, Calif. Abstract 533.

共引文献32

同被引文献104

引证文献6

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部